## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.7% below STRENGTH zone (4.0-10.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($120.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Abbott Laboratories Stock After Hours (ABT): FDA Win, Holiday Trading Dynamics, and What to Watch Before the Dec. 24 Open**
- Source: ts2.tech | 20251224T020823 | Bullish | Relevance: 100%
- Abbott Laboratories (ABT) closed slightly lower on December 23, 2025, despite receiving FDA approval for its Voltâ„¢ Pulsed Field Ablation (PFA) System for atrial fibrillation. The article discusses ABT's after-hours performance, the significance of the FDA approval for its medical device growth, and what investors should watch for in the holiday-shortened trading session on December 24, including macro data, key trading levels, and the company's recently increased dividend.

**2. Abbott receives clearance for heart delivery device in premature babies**
- Source: MedTech Dive | 20251222T194022 | Bullish | Relevance: 100%
- Abbott has secured clearance for its Amplatzer Piccolo Delivery System, designed to treat life-threatening heart openings in premature infants. This device aims to make procedures safer and easier for physicians, complementing Abbott's Amplatzer Piccolo Occluder which has been in use since 2019. The new system is set to be sold in the U.S. and the European Union, building on years of physician feedback.

**3. Abbott earns FDA approval for Volt PFA system for AFib**
- Source: MassDevice | 20251222T140352 | Bullish | Relevance: 100%
- Abbott has received FDA approval for its Volt pulsed field ablation (PFA) system for treating atrial fibrillation (AFib), making it a new competitor in the U.S. PFA market. The system offers a single-catheter PFA approach, designed for improved workflow and procedural flexibility, and allows for conscious sedation, potentially leading to faster recovery times. This approval, based on strong data from the VOLT-AF IDE study, was granted ahead of analyst expectations and is anticipated to intensify competition in the PFA market.

**4. Abbott Gets FDA Approval for Volt Medical Device to Treat Arrhythmia**
- Source: marketscreener.com | 20251222T100600 | Bullish | Relevance: 100%
- Abbott has received FDA approval for its Volt Pulsed Field Ablation System, designed to treat atrial fibrillation (AFib), a common heart rhythm disorder. The company will soon begin commercializing the device in the U.S., leveraging strong safety and efficacy data from a supporting study. Abbott had previously secured European Union approval and has been selling a version of the device there.

**5. Swedbank AB Sells 179,009 Shares of Abbott Laboratories $ABT**
- Source: MarketBeat | 20251224T131852 | Bullish | Relevance: 100%
- Swedbank AB reduced its stake in Abbott Laboratories by 11.1% in Q3, selling 179,009 shares and retaining 1,435,313 shares valued at approximately $192.25 million. Analysts maintain a "Moderate Buy" rating for ABT with a consensus price target of $147. Abbott Laboratories reported Q3 EPS in line with estimates, provided FY2025 guidance, and increased its quarterly dividend to $0.63 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.12M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.0x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $217.2B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.0 |
| Current P/E | 24.1 |
| YoY Growth | 9.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.1% to -1.7% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >4.0% for momentum thesis). Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 46. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.69% (CS: 32) | Neutral |
| RSI_14 | 45.9 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 0.987x | Below |
| vs SMA200 | 0.958x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $124.72
- **Stop Loss:** $120.02 (3.8% risk)
- **Target:** $129.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 255
- **Position Value:** $31,803.60
- **Portfolio %:** 31.80%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*